Skip to main content

Ahead of FDA meeting, S.F. biotech's stock dips on questions about data analysis

The company's anemia drug for chronic kidney disease patients, which originally faced an FDA decision date in December, is set to be reviewed by a panel of experts.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.